Prelude Therapeutics

PRLDNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$390.262 M

$4.90 +4.70%

Close of 7 Aug 2026

Revenue

$12.1M

#3133 by revenue

Earnings

-$99.5M

Loss-making

Shares outstanding

63,002,248

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#224Upstream BioUPB$394.5M
#225Rocket PharmaceuticalsRCKT$394.2M
#226Prelude TherapeuticsPRLD$390.3M
#227DiaMedica TherapeuticsDMAC$363.7M
#228Lyell ImmunopharmaLYEL$360.5M

Where these numbers come from

Share counts and financials for Prelude Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.